Drug Kinetics
BMS Battles Deeply Ingrained Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates
Bristol Myers Squibb; Cobenfy; schizophrenia; prescribing habits; dopamine D2 receptor; novel mechanism of action; quarterly earnings; drug market uptake; Alzheimer’s disease psychosis; atypical antipsychotics
Agios’ Pyrukynd Misses Primary Endpoint in First Pediatric Study for Rare Blood Disorder
Agios Pharmaceuticals, Pyrukynd, mitapivat, PK deficiency, pediatric study, blood disorder, Phase 3 ACTIVATE-KidsT study